Last reviewed · How we verify
Retagliptin Phosphate Tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Retagliptin Phosphate Tablet (Retagliptin Phosphate Tablet) — Jiangsu HengRui Medicine Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Retagliptin Phosphate Tablet TARGET | Retagliptin Phosphate Tablet | Jiangsu HengRui Medicine Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Retagliptin Phosphate Tablet CI watch — RSS
- Retagliptin Phosphate Tablet CI watch — Atom
- Retagliptin Phosphate Tablet CI watch — JSON
- Retagliptin Phosphate Tablet alone — RSS
Cite this brief
Drug Landscape (2026). Retagliptin Phosphate Tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/retagliptin-phosphate-tablet. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing